1. Home
  2. MNRO vs CBIO Comparison

MNRO vs CBIO Comparison

Compare MNRO & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monro Inc.

MNRO

Monro Inc.

HOLD

Current Price

$16.57

Market Cap

505.8M

ML Signal

HOLD

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$18.14

Market Cap

557.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNRO
CBIO
Founded
1957
2003
Country
United States
United States
Employees
N/A
44
Industry
Automotive Aftermarket
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
505.8M
557.8M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
MNRO
CBIO
Price
$16.57
$18.14
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$16.00
$26.67
AVG Volume (30 Days)
698.1K
297.1K
Earning Date
05-27-2026
04-29-2026
Dividend Yield
6.69%
N/A
EPS Growth
N/A
N/A
EPS
0.26
N/A
Revenue
$1,195,334,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.59
$279.20
P/E Ratio
$68.19
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.24
$8.72
52 Week High
$23.91
$27.41

Technical Indicators

Market Signals
Indicator
MNRO
CBIO
Relative Strength Index (RSI) 46.20 44.96
Support Level $16.19 $10.83
Resistance Level $17.06 $20.58
Average True Range (ATR) 0.79 2.53
MACD 0.01 -0.85
Stochastic Oscillator 19.46 24.32

Price Performance

Historical Comparison
MNRO
CBIO

About MNRO Monro Inc.

Monro Inc is an operator of retail tire and automotive repair stores in the United States. The company offers replacement tires and tire related services, automotive undercar repair services, and a broad range of routine maintenance services, on passenger cars, light trucks, and vans. It also provides other products and services for brakes; mufflers and exhaust systems; and steering, drive train, suspension, and wheel alignment.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: